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The adipocyte-derived protein adiponectin is highly heritable and inversely associated with risk of type 2 diabetes mellitus
(T2D) and coronary heart disease (CHD). We meta-analyzed 3 genome-wide association studies for circulating adiponectin
levels (n=8,531) and sought validation of the lead single nucleotide polymorphisms (SNPs) in 5 additional cohorts
(n=6,202). Five SNPs were genome-wide significant in their relationship with adiponectin (P#5610
28). We then tested
whether these 5 SNPs were associated with risk of T2D and CHD using a Bonferroni-corrected threshold of P#0.011 to
declare statistical significance for these disease associations. SNPs at the adiponectin-encoding ADIPOQ locus demonstrated
the strongest associations with adiponectin levels (P-combined=9.2610
219 for lead SNP, rs266717, n=14,733). A novel
variant in the ARL15 (ADP-ribosylation factor-like 15) gene was associated with lower circulating levels of adiponectin
(rs4311394-G, P-combined=2.9610
28, n=14,733). This same risk allele at ARL15 was also associated with a higher risk of
CHD (odds ratio [OR]=1.12, P=8.5610
26, n=22,421) more nominally, an increased risk of T2D (OR=1.11, P=3.2610
23,
n=10,128), and several metabolic traits. Expression studies in humans indicated that ARL15 is well-expressed in skeletal
muscle. These findings identify a novel protein, ARL15, which influences circulating adiponectin levels and may impact upon
CHD risk.
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Introduction
Adiponectin is an adipocyte-secreted protein that increases
insulin sensitivity [1,2,3], and has anti-diabetic [4,5,6] and anti-
atherogenic effects [7]. Several features render adiponectin an
attractive and tractable biomarker for large epidemiologic studies,
such as its long half-life, high ex vivo stability, and minimal diurnal
variability [8,9].
While adiponectin levels are highly heritable (30–70%)
[10,11,12], several well-designed studies have shown variable
association between common polymorphisms in the adiponectin
gene (ADIPOQ), possibly due to small sample sizes and different
panels of single nucleotide polymorphisms (SNPs), ethnicities and
clinical outcomes [12,13,14]. This has lead some observers to call
for a more complete and systematic characterization of the genetic
determinants of adiponectin levels [12].
Adiponectin Genome-Wide Association Study
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are the common genetic determinants of adiponectin levels both at
ADIPOQ and elsewhere? And second, do the variants robustly
associated with adiponectin levels influence metabolic traits and
risk of metabolic disease?
To comprehensively assess the influence of common genetic
variation on circulating adiponectin levels, we undertook a large-
scale meta-analysis of 3 genome-wide association studies (GWAS)
for circulating adiponectin levels from population-based cohorts
(n=8,531 participants). From this first stage, we chose SNPs most
strongly associated with adiponectin levels (P,10
24, n=250), and
tested these for their association with adiponectin in 5 additional
population-based cohorts (n=6,202). The 5 SNPs which achieved
genome-wide significance in the combined stage were then tested
for their association with: type 2 diabetes mellitus (T2D) in the
Diabetes Genetics Replication And Meta-analysis (DIAGRAM)
consortium [15] (n=10,128); indices of insulin resistance in the
Meta-Analysis of Glucose and Insulin-related traits Consortium
(MAGIC) [16] (n=24,188); risk of coronary heart disease (CHD)
in a consortium of 8 cohorts with available genome-wide
association data (n=22,421); and body mass index (BMI) in the
Genetic Investigation of Anthropometric Traits (GIANT) consor-
tium (Text S1) [17,18] (n=32,527) (Figure 1).
Results
Genome-Wide Association Study for Circulating
Adiponectin Levels
To identify genetic variants influencing adiponectin levels, we
performed a GWAS utilizing information from population-based
cohorts including, in total, 14,733 subjects of European descent
(Table 1). We identified 5 variants at 2 loci that achieved genome-
wide significance (P#5610
28) for their relationship with circulat-
ing adiponectin levels (Table 2). The SNP most strongly associated
with circulating adiponectin levels lies 30 kb upstream of the
ADIPOQ locus (rs266717; P-combined=9.2610
219) (Table 2,
Figure S1, Figure S2). In total, 4 SNPs at the ADIPOQ locus
demonstrated genome-wide significant associations with circulat-
ing adiponectin. All 8 studies contributed to these genome-wide
significant associations, with the exception of rs6444175, which
demonstrated some heterogeneity across cohorts (Table 2).
Our results also identified a novel intronic SNP (rs4311394)
located in the ARL15 (ADP-ribosylation factor-like 15) gene whose
G allele was robustly associated with decreased adiponectin levels
(P=2.9610
28) (Table 2, Table S3, Figure 2). ARL15 is an ADP-
ribosylation factor-like GTP-binding protein, whose function is
unknown, yet belongs to a family of proteins involved in
intracellular vesicle trafficking [19].
Association with Metabolic Disease and Metabolic Traits
Since glycemia, T2D and CHD have been correlated with
adiponectin levels, we tested whether genome-wide significant
SNPs for adiponectin levels were associated with glycemia, indices
of insulin resistance, and risk of T2D and CHD. Since 5 SNPs
(which, due to linkage disequilibrium, represented 4.59 indepen-
dent statistical tests [see Methods]) were tested for their association
with T2D, CHD and metabolic traits, we employed a conservative
Bonferroni-corrected threshold of a=0.011 (where 0.011=0.05/
4.59) to declare statistical significance for these metabolic diseases
and traits. None of the SNPs at the ADIPOQ locus demonstrated a
robust relationship with T2D, CHD, homeostasis model assess-
ment insulin resistance (HOMA-IR), homeostasis model assess-
ment beta-cell function (HOMA-B) or BMI (Table 3, Table 4,
Table S4). However rs1648707, at ADIPOQ, was associated with a
non-statistically significant trend for its relationship with CHD
(P=0.04) and T2D (P=0.046).
In contrast, the risk allele rs4311394-G at ARL15,w h i c hw a s
associated with lower adiponectin levels, was also associated with: an
increased risk of CHD in a consortium of 7 CHD cohorts (Odds
ratio [OR]=1.12, [95% Confidence Interval [CI]: 1.06, 1.17],
P=8.5 610
26, n=22,421); an increased risk of T2D in the
DIAGRAM consortium [15] (OR=1.11 [95% CI: 1.03, 1.18],
P=3.2 610
23, n=10,128); and higher glycated hemoglobin in the
European Prospective Investigation of Cancer-Norfolk (EPIC-Nor-
folk) cohort (0.025% per G allele [95% CI: 0.01, 0.04], P=5.0610
24,
n=14,168) (Table 3). In the MAGIC consortium [16], the rs4311394-
G allele was associated with increased levels of fasting insulin
(P=2.3610
23, n=24,614), and demonstrated non-significant trends
Figure 1. Overall study design.
doi:10.1371/journal.pgen.1000768.g001
Author Summary
Through a meta-analysis of genome-wide association
studies of 14,733 individuals, we identified common
base-pair variants in the genome which influence circulat-
ing adiponectin levels. Since adiponectin is an adipocyte-
derived circulating protein which has been inversely
associated with risk of obesity-related diseases such as
type 2 diabetes (T2D) and coronary heart disease (CHD),
we next sought to understand if the identified variants
influencing adiponectin levels also influence risk of T2D,
CHD, and several metabolic traits. In addition to confirm-
ing that variation at the ADIPOQ locus influences
adiponectin levels, our analyses point to a variant in the
ARL15 (ADP-ribosylation factor-like 15) locus which de-
creases adiponectin levels and increases risk of CHD and
T2D. Further, this same variant was associated with
increased fasting insulin levels and glycated hemoglobin.
While the function of ARL15 is not known, we provide
insight into the tissue specificity of ARL15 expression.
These results thus provide novel insights into the
physiology of the adiponectin pathway and obesity-
related diseases.
Adiponectin Genome-Wide Association Study
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(P=0.02, n=24,130) (Table 4). In the GIANT consortium [17], the
same allele demonstrated a modest and non-significant association
with decreased BMI (P=0.016, n=32,527) (Table S4), indicating that
the disease and metabolic trait associations of rs4311394-G are
unlikely to be mediated through an increase in BMI.
Thus, in sum, the G allele at rs4311394 was consistently
associated with an increased risk of T2D and CHD, as well as
deleterious changes in the 5 metabolic traits tested.
Expression Studies
Since the function and distribution of ARL15 expression is
unknown, we assessed the level of ARL15 mRNA expression in
human tissues using quantitative real-time PCR across a wide
set of human tissues. We identified that ARL15 was expressed
most abundantly in skeletal muscle at a level 4-fold that of the
mean of all other tissues, with adipose expression detectable but
low (Figure 3). Using biopsied tissue from insulin-sensitive
tissues (liver, skeletal muscle and adipose tissue) in healthy
volunteers, immunoblots confirmed ARL15 expression in
skeletal muscle, although it was detectable in all 3 tissues
(Figure 4).
Discussion
By conducting a GWAS for the adipocyte-derived protein
adiponectin, we have identified a novel susceptibility variant in
ARL15, which is associated with lower adiponectin levels and
increased risk of T2D and CHD. Our results also help clarify
which variants at ADIPOQ influence adiponectin levels, thus
expanding our understanding of the adiponectin pathway.
ARL15 is widely expressed [20]. However its function is unknown,
and there have been no phenotypes previously associated with this
gene. Based on its predicted protein sequence, ARL15 is structurally
similar to ADP-ribosylation factors and Ras-related GTP-binding
proteins which play key roles in the regulation of intracellular vesicle
trafficking [19], and whichhave been specificallyimplicated in insulin
signaling and insulin-stimulated glucose transport [21,22,23,24]. Our
preliminary data demonstrate that ARL15 is expressed in insulin-
responsive tissues, including adipose tissue. Interestingly, expression
was highest in skeletal muscle, which is the main site of insulin-
mediatedglucosedisposal,butwhichdoesnotsynthesizeadiponectin.
Thus, ARL15 is a good candidate to be involved in cellular insulin
resistance and/or adiponectin trafficking and secretion. Its implica-
tion in metabolic diseases by a non-hypothesis-based genetic
approach provides strong impetus for further functional studies.
Table 1. Participant characteristics (n total for all cohorts=14,733).
Study
Number of
Subjects
(% Women)
Method of
Adiponectin
Measurement
Adiponectin
(mg/ml) (SD)
Adiponectin
Males (mg/ml)
(SD)
Adiponectin
Females (mg/ml)
(SD) Age (SD) BMI (SD)
Discovery
Samples
TwinsUK 1399 (100) ELISA{ 8.1 (3.9) - 8.1 (3.9) 48.5 (13.1) 25.1 (4.7)
GEMS 1751 (59.3) ELISA{ 6.8 (4.8) 5.8 (4.0) 8.3 (5.5) 52.5 (9.5) 28.5 (3.6)
CoLaus 5381 (47.8) ELISA{ 10.1 (8.1) 7.4 (5.4) 12.4 (9.4) 53.2 (10.8) 25.8 (4.6)
Replication
Samples
BLSA 562 (52.9) RIA{ 13.4 (8.5) 11.5 (7.7) 15.4 (8.9) 67.9 (13.8) 26.8 (4.5)
EPIC-Norfolk 970 (35.5) ELISA* 6.9 (3.9) 5.6 (2.7) 9.1 (4.6) 62.1 (8.2) 28.3 (4.2)
Framingham 2228 (54.6) ELISA* 10.5 (6.4) 7.6 (4.5) 13.0 (6.8) 60.4 (9.5) 27.8 (5.0)
InCHIANTI 1027 (54.7) RIA{ 13.5 (9.8) 10.5 (7.6) 15.9 (10.8) 67.6 (15.3) 27.1 (4.1)
ALSPAC 1415 (51.3) ELISA* 13.1 (5.3) 12.8 (5.1) 13.3 (5.5) 9.9 (0.3) 17.7 (2.9)
*Plasma.
{Serum.
SD: Standard Deviation, GEMS: Genetic Etiology of Metabolic Syndrome, BLSA: Baltimore Longitudinal Study of Aging, EPIC-Norfolk: European Prospective Investigation
of Cancer-Norfolk, ALSPAC: Avon Longitudinal Study of Parents and Children, ELISA: Enzyme-Linked Immunosorbent Assay, RIA: Radio-Immunoassay, BMI: Body Mass
Index.
doi:10.1371/journal.pgen.1000768.t001
Table 2. Relationship of SNPs achieving genome-wide significance for their association with adiponectin levels (n=14,733 from
the 8 studies in Table 1).
Locus Chr SNP
Allele
(A1*/A2) MAF
Effect Size on Ln- Transformed
Adiponectin (95% CI)
Change in Adiponectin (mg/ml)
for Each Effect Allele P-Value
Q-Test
P-Value
ARL15 5 rs4311394 G*/A 0.41 20.04 (20.06, 20.03) 0.96 2.9E-08 0.38
ADIPOQ 3 rs6444175 G/A* 0.28 20.08 (20.1, 20.07) 0.92 1.2E-21 0.005
ADIPOQ 3 rs266717 T/C* 0.48 0.07 (0.05, 0.09) 1.07 9.2E-19 0.67
ADIPOQ 3 rs1426810 G*/A 0.42 0.07 (0.05, 0.08) 1.07 2.2E-18 0.15
ADIPOQ 3 rs1648707 C*/A 0.07 20.06 (20.07, 20.04) 0.94 3.0E-12 0.42
A1=Effect Allele.
*Minor Allele. Effect Size is the change in Natural Log-Transformed adiponectin levels per effect allele.
Chr: Chromosome, SNP: Single Nucleotide Polymorphism, MAF: Minor Allele Frequency, CI: Confidence Interval.
doi:10.1371/journal.pgen.1000768.t002
Adiponectin Genome-Wide Association Study
PLoS Genetics | www.plosgenetics.org 4 December 2009 | Volume 5 | Issue 12 | e1000768Our study sheds further light on the role of ADIPOQ SNPs on
adiponectin levels — which has been the source of several
inconsistent reports [12,13,14,25] — since we have systematically
tested all common HapMap CEPH (Centre d’E ´tude du Polymor-
phisme Humain) SNPs through genotyping and imputation across
the ADIPOQ locus in 14,733 individuals (Figure S2).Among the SNPs
Figure 2. Association between SNPs near ARL15 and adiponectin levels. (A) 2Log(P-value) measures for associationbetween single nucleotide
polymorphisms (SNPs) and chromosomal position. (B) Linkage disequilibrium in GOLD heat map Haploview 4.0 color scheme, CEPH (Centre d’E ´tude du
Polymorphisme Humain) population. The x axis represents genomic position in Mb (A) and in kb (B). All P-values are derived from the discovery meta-
analysis of CoLaus, TwinsUK, and Genetic Etiology of Metabolic Syndrome (GEMS) cohorts, except that for the lead SNP, rs4311394 (in red), which is
derived from the combined P-value from the CoLaus, TwinsUK, GEMS, Framingham, InCHIANTI, Baltimore Longitudinal Study of Aging (BLSA), Avon
Longitudinal Study of Parents and Children (ALSPAC), and European Prospective Investigation of Cancer-Norfolk (EPIC-Norfolk) cohorts.
doi:10.1371/journal.pgen.1000768.g002
Table 3. Association of genome-wide significant SNPs with risk of type 2 diabetes mellitus (T2D) and coronary heart disease (CHD)
(n=10,128 for T2D; n=22,421 for CHD).
Locus SNP Effect Allele Odds Ratio (95% CI) for T2D P-Value for T2D Odds Ratio (95% CI) for CHD P-Value for CHD
ARL15 rs4311394 G 1.11 (1.03, 1.18) 0.0032 1.12 (1.06, 1.17) 8.5610
26
ADIPOQ rs6444175 G 0.99 (0.93, 1.07) 0.86 0.97 (0.93, 1.01) 0.14
ADIPOQ rs266717 T 1 (0.94, 1.07) 0.98 0.98 (0.94, 1.02) 0.29
ADIPOQ rs1426810 G 1.01 (0.94, 1.07) 0.86 0.96 (0.92, 0.998) 0.04
ADIPOQ rs1648707 C 1.06 (1, 1.13) 0.046 1.05 (1.003, 1.09) 0.04
SNP: Single Nucleotide Polymorphism, CI: Confidence Interval.
doi:10.1371/journal.pgen.1000768.t003
Adiponectin Genome-Wide Association Study
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rs1648707 SNP achieved genome-wide significance in our analysis
for adiponectin. rs1648707 is in moderate linkage disequilibrium with
rs266729 (r
2=0.74), which has previously been associated with
adiponectin levels, but not consistently with T2D [12]. We did not
assess rare variants, and were thus unable to test the association of
rs17366743 (minor allele frequency=0.075) with adiponectin levels,
which has been previously associated with T2D and with fasting
glucose, but not with adiponectin levels [13].
Interestingly, ADIPOQ SNPs that showed genome-wide signif-
icant associations with adiponectin levels did not show associations
with T2D or CHD. This raises the question of how ARL15
interacts with adiponectin to influence disease risk. The demon-
strated relationship of ARL15 with the metabolic traits and diseases
may represent adiponectin-independent effects of ARL15 —a
hypothesis that could be tested by adjusting the relationship
between ARL15 and CHD or T2D for adiponectin levels (which
was not possible in this study, as the disease cohorts had no
measured adiponectin levels). Alternatively, recent evidence
suggests that adiponectin may be influenced directly by insulin
exposure [26–35], allowing adiponectin to act as a surrogate
marker for integrated total insulin exposure as a result of its stable
half-life and relatively low diurnal variability. Consequently,
ARL15 may be an upstream mediator of the relationship between
insulin and adiponectin, and may thus impact upon T2D and
CHD through an insulin-dependent pathway which involves, but
is not entirely dependent upon, adiponectin. In addition, since we
demonstrated that the ARL15 variant was associated with
adiponectin levels across all age ranges, including children in the
Avon Longitudinal Study of Parents and Children (ALSPAC)
cohort, this variant likely affects lifelong adiponectin levels, which
may influence its relationship with T2D and CHD.
In conclusion, this study expands our understanding of the
genetic influences on adiponectin levels. We have implicated a
novel locus, ARL15, in the regulation of adiponectin levels and
clarified the role of variants near ADIPOQ on adiponectin levels.
Finally, we provide further evidence that the variant at ARL15
may influence risk of T2D and CHD, thus providing impetus for
further study of ARL15.
Methods
We undertook a GWAS to detect SNPs which were associated
with adiponectin, and tested the physiologic and clinical relevance
of these SNPs by assessing their association with indices of glucose
homeostasis and BMI in European populations, and with T2D
and CHD in large clinical cohorts (Figure 1).
Ethical Considerations
All studies including biopsy of liver, skeletal muscle or adipose
tissue from healthy volunteers for immunoblotting studies were
approved by institutional ethics review committees at the relevant
organizations. All participants provided informed written consent.
Table 4. Association of genome-wide significant SNPs with indices of insulin homeostasis.
Locus SNP Effect Allele
Insulin Effect Size
(95% CI) [n=24,616] Insulin P-Value
HOMA-IR Effect
(95% CI) [n=24,188]
HOMA-IR
P-Value
HOMA-B Effect
(95% CI) [n=24,130]
HOMA-B
P-Value
ARL15 rs4311394 G 0.014 (0.005, 0.023) 2.0610
23 0.012 (0.002, 0.021) 0.01 0.009 (0.001, 0.017) 0.02
ADIPOQ rs6444175 G 0.002 (20.006, 0.011) 0.62 0.005 (20.004, 0.014) 0.30 0.003 (20.005, 0.01) 0.45
ADIPOQ rs266717 T 20.003 (20.011, 0.005) 0.46 20.001 (20.01, 0.007) 0.76 20.006 (20.013, 0.001) 0.08
ADIPOQ rs1426810 G 0 (20.008, 0.008) 0.99 0.001 (20.007, 0.01) 0.81 20.002 (20.009, 0.005) 0.63
ADIPOQ rs1648707 C 0.009 (0.001, 0.017) 0.032 0.007 (20.001, 0.016) 0.10 0.003 (20.004, 0.01) 0.41
SNP: Single Nucleotide Polymorphism, CI: Confidence Interval, HOMA-IR: Homeostasis Model Assessment Insulin Resistance, HOMA-B: Homeostasis Model Assessment
Beta-Cell Function.
doi:10.1371/journal.pgen.1000768.t004
Figure 3. Tissue distribution of ARL15 expression. mRNA levels
determined by quantitative real-time PCR in a panel of human tissues.
doi:10.1371/journal.pgen.1000768.g003
Figure 4. Western blot showing ARL15 expression in insulin-
responsive tissues in humans with a-tubulin as a loading
control. HEK293=untransfected HEK293 cells; ARL15=HEK293 cells
transiently expressing wild type human ARL15. SkM=skeletal muscle;
WAT=white adipose tissue.
doi:10.1371/journal.pgen.1000768.g004
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The first stage of the GWAS for adiponectin levels was
performed in 3 population-based cohorts utilizing subjects of self-
described European ancestry, which were not selected for
diabetes, heart disease or any metabolic trait (Table 1). The
discovery cohorts included CoLaus [36], TwinsUK [37,38], and
Genetic Etiology of Metabolic Syndrome (GEMS) [39]. Partic-
ipants of the CoLaus study were individuals of European
ancestry, randomly selected from 56,694 permanent residents of
Lausanne, Switzerland, between the ages of 35 and 75 years.
Recruitment took place between April 2003 and March 2006.
TwinsUK is a population-based sample of British twins, which is
representative of the general United Kingdom population, and is
extensively phenotyped for aging-related traits [40]. GEMS is a
case-control study of dyslipidemic individuals between the ages of
20 and 65 years. Cases and controls were matched based on
gender and recruitment site. The GEMS and CoLaus studies
were sponsored in part by GlaxoSmithKline. All participants
were informed of this sponsorship, and consented for the use of
their data and biologic samples by GlaxoSmithKline and its
subsidiaries.
The validation cohorts included the Framingham Offspring
Study (FOS) [13], Baltimore Longitudinal Study of Aging (BLSA)
[41], InCHIANTI [42,43], ALSPAC [44] and EPIC-Norfolk [45].
The FOS is a population-based sample of residents of Framing-
ham, Massachusetts. Adiponectin was measured at exam 7 (1998–
2002). BLSA is an observational study that began in 1958 to study
normative aging in a cohort of healthy persons 17 years of age and
older at study entry. InCHIANTI is a population-based cohort
designed to study aging-related traits and disease from the Chianti
geographic region (Tuscany, Italy). ALSPAC is a population-based
birth cohort study consisting initially of over 13,000 women and
their children recruited in the county of Avon, UK, in the early
1990s. The EPIC-Norfolk cohort is a British population-based
study of white persons recruited from Norfolk, UK, between 1993
and 1997. All individuals in all replication cohorts were of self-
described European descent.
Phenotyping and Genotyping for Metabolic Traits, T2D,
and CHD
Only the SNPs which achieved genome-wide significance for
adiponectin levels in the combined analysis of data from all 8
cohorts were assessed for their relationship with adiposity-driven
diseases and traits, which included: T2D, CHD, fasting glucose,
glycated hemoglobin, BMI and insulin, as well as measures of
insulin resistance (HOMA-IR) and beta-cell function (HOMA-B)
estimated by the homeostasis model [46].
T2D risk was estimated from the DIAGRAM consortium (a
meta-analysis of 3 T2D genome-wide association scans [http://
www.well.ox.ac.uk/DIAGRAM/], which included 4,107 T2D
cases and 5,187 controls). The 3 populations were the Wellcome
Trust Case Control Consortium (WTCCC), the Finland-United
States Investigation of NIDDM [Non-Insulin-Dependent Diabetes
Mellitus] Genetics (FUSION), and the Diabetes Genetics Initiative
(DGI). A full description of this meta-analysis is available
elsewhere [15,47].
The association between susceptibility alleles and fasting
glucose, insulin and measures of insulin resistance and beta-cell
function were tested in MAGIC [16]. This consortium includes
data from 36,610 individuals of European descent who were
included in 4 distinct consortia: [a] The European Network for
Genetic and Genomic Epidemiology (ENGAGE) project, com-
bining data from deCODE, Northern Finland Birth Cohort 1966,
Netherlands Twins Register/Netherlands Study of Depression and
Anxiety and the Rotterdam study; [b] the GEMS study, which
includes data from the CoLaus and TwinsUK scans; [c] DFS,
which includes the DGI, FUSION and SardiNIA scans; and [d]
the Framingham Heart Study. Details of all of these studies,
phenotyping and genotyping protocols have been published
previously [16].
The association between susceptibility alleles and CHD was
tested in 8 cohorts (n=22,421). These cohorts included PennCath
[48], MedStar, the Ottawa Heart Study [49], the WTCCC
coronary heart disease (CAD) study [50,51], a case-control study
of CHD nested in the EPIC-Norfolk cohort comprising partici-
pants with available genome-wide data [52], German Myocardial
Infarction Family Study (GerMIFS) I and GerMIFS II [50,53],
and the Rotterdam Study [54] (Table S2). The rs4311394 SNP
was assessed by imputation in the GerMIFS I cohort, and did not
meet quality control criteria. Thus, results for this SNP are
reported for all cohorts except GerMIFS I (Figure S3). All other
SNPs were assessed in all cohorts.
Associations with BMI were tested in the GIANT consortium
[17,18], which encompasses 15 cohorts of 32,527 individuals of
European descent. It has been described in detail previously,
including information on genotyping and phenotyping [17].
Genotyping
Table S1 outlines the genotyping methods used for each cohort,
individual and SNP exclusion thresholds, and imputation
algorithms. For the CoLaus and GEMS studies, genotypes were
obtained using the Affymetrix Genechip Human Mapping 500k
array with the Bayesian Robust Linear Modeling using Mahala-
nobis distance (BRLMM) algorithm [52]. The TwinsUK samples
were genotyped using the Illumina calling algorithm on the
Illumina HumanHap300, HumanCNV370 Duo and HumanHap
550 [40]. The FOS employed the Affymetrix 500k and MIPS 50k
genotyping arrays. Both the BLSA and InCHIANTI cohorts used
the Illumina Human Hap 550 genotyping arrays, while the
Illumina Human Hap300 array was used in the ALSPAC cohort.
Targeted genotyping was performed in the EPIC-Norfolk cohort
using TaqMan SNP genotyping assay (Applied Biosystems,
Warrington, UK) according to the manufacturer’s protocol.
Genotype frequencies were in Hardy Weinberg Equilibrium
(HWE) (P.0.50), call rates were .94% and concordances were
.98% for the TaqMan assay.
Adiponectin Measurement
The TwinsUK and EPIC-Norfolk cohorts measured adiponec-
tin levels with an in-house 2-site enzyme-linked immunosorbent
assay (ELISA) using antibodies and standards from R&D Systems
Europe (Abingdon, Oxford, UK) in plasma. The day-to-day
coefficients of variation (CV) for adiponectin were 5.4%, 5.2%,
and 5.8% at a concentration of 3.6 mg/ml, 9.2 mg/ml, and
15.5 mg/ml, respectively [38]. The FOS, CoLaus and GEMS
measured adiponectin using the ELISA assay (R&D Systems,
Minneapolis, Minnesota, United States of America; Intra-assay
CV: 5.8%) [13]. Importantly, while CoLaus and GEMs measured
adiponectin in plasma, the FOS measured adiponectin in serum.
The ALSPAC cohort measured adiponectin using a commercially
available ELISA kit (R&D systems, Oxon, UK) previously
validated against the corresponding radio-immunoassay (RIA).
The inter-assay CV for this adiponectin assay was ,7.5%. The
InCHIANTI and BLSA studies measured adiponectin levels using
the adiponectin RIA assay of Linco Research (St. Charles,
Missouri, USA). The detectable ranges for the RIA assay used
in InCHIANTI and BLSA are 0.78 mg/ml–200 mg/ml.
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Relative levels of ARL15 mRNA in human tissues were assessed
by quantitative real-time PCR of a commercially available human
tissue panel of RNA (AMS Biotechnology, Abingdon, UK). 500 ng
of RNA were reverse-transcribed using 125 ng of random
hexamers and 500 mM deoxynucleotide triphosphates (dNTPs)
(both from Promega, Madison, Wisconsin, USA) and 500 ng of
Superscript III reverse transcriptase (Invitrogen). Gene expression
was quantified on an ABI7900 Real-Time PCR system (Applied
Biosystems, Foster City, California, USA) in TaqMan Mastermix
(Applied Biosystems). Primers and probe for ARL15 were supplied
by Applied Biosystems (ABI Hs00219491_m1), and ARL15
expression was normalized to expression of PPIA (Cyclophilin
A). PPIA primers (59-ACGGCGAGCCCTTGG-39 (sense), 59-
TTTCTGCTGTCTTTGGGACCT-39 (antisense)) and probe
(59-[FAM] CGCGTCTCCTTTGAGCTGTTTGCA[TAMRA]-
39) were synthesized by Sigma-Aldrich. Skeletal muscle biopsies
were a gift from Dr Anna Krook, from the Karolinska Institute.
Frozen skeletal muscle, liver and white adipose tissue samples were
homogenized in lysis buffer (50 mM Tris-HCl, pH8.0, 150 mM
NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, and Complete
Protease Inhibitor Cocktail [Roche]), and cell debris removed by
centrifugation. Cleared supernatants were boiled in sodium
dodecyl sulphate (SDS) sample buffer and run on an SDS
polyacrylamide gel before transfer to a polyvinylidene difluoride
(PVDF) membrane (Amersham) and subsequent immunoblotting
with either purified rabbit anti-human ARL15 antibody (Protein-
tech Group) or anti-a-tubulin antibody (sc-8035; Santa Cruz
Biotechnology). Full-length human wild type ARL15 cDNA was
purchased from Open Biosystems and subcloned into pCDNA 3.1
(Invitrogen) using the XhoI and HindIII restriction sites. HEK293
cells (American Type Culture Collection [ATCC]) were transient-
ly transfected using the CalPhos Mammalian Tranfection Kit
(Clontech) according to the manufacturer’s instructions.
Statistical Methods
In all cohorts, the adiponectin concentrations were natural
logarithm transformed to create a normally distributed phenotype.
Adiponectin levels were subsequently adjusted for age, sex and
BMI — important correlates of adiponectin levels [4,5]. All results
reported for association of genetic variants with adiponectin levels
are adjusted for age, sex and BMI. All statistical tests assumed an
additive effect of the effect allele. In the TwinsUK cohort, we
found that there was little difference when comparing results both
adjusted, and unadjusted, for BMI (the Spearman coefficients for
the beta coefficients was 0.94 and 1.0 for P-values [P-values for
both Spearman coefficients,1610
25]).
The SNPTEST software program [51] was used to perform
genome-wide association testing in the GEMS and CoLaus
cohorts, while the Merlin software package [55] was used to
perform association testing in the TwinsUK cohort. The meta-
analysis of the discovery phase cohorts (CoLaus, TwinsUK and
GEMS) was performed using Liptak-Stouffer’s method for
combination of independent tests, where P-values are converted
to Z-scores by a standard normal curve and weighted by each
study’s sample size [56].
All SNPs that achieved a combined P-value of #10
24 in
the meta-analysis (n=250) were tested for their association in
the additional cohorts (InCHIANTI, BLSA, ALSPAC and the
Framingham Offspring Cohort). Two SNPs that were not near the
ADIPOQ locus, and which demonstrated associations of #5610
27
with adiponectin levels in the combined analysis, were further
verified in an additional replication cohort (EPIC-Norfolk), where
association with adiponectin was tested using a generalized linear
model. For the quantitative trait analyses, individuals with known
T2D were excluded. For the T2D case-control analyses, each SNP
was tested for association using a logistic regression analysis,
adjusted for age, sex and BMI. All analyses for the EPIC-Norfolk
cohort were performed with SAS 9.1 (SAS Institute Inc., Cary,
North Carolina, USA). To perform a meta-analysis of all
replication and discovery cohorts, we employed inverse-variance
techniques in the STATA software package (College Station,
Texas, USA).
We declared statistical significance in the GWAS as P#5610
28,
where this threshold is based on a Bonferroni correction of
a=0.05 divided by one million, the estimated number of
independent common tests among common SNPs in the CEU
population of the HapMap II project [57]. Using this threshold, 5
SNPs achieved genome-wide significance for their relationship
with circulating adiponectin levels in the combined analysis of all
adiponectin cohorts. These were subsequently tested for their
association with glycated hemoglobin, indices of insulin resistance,
beta-cell function and risk of T2D and CHD. The number of
independent statistical tests represented by these 5 SNPs,
accounting for linkage disequilibrium at ADIPOQ, was assessed
by spectral decomposition of matrices of pairwise linkage
disequilibrium between the 4 SNPs at the ADIPOQ locus [58].
In total, 3.59 independent statistical tests were performed at this
locus, and one at the ARL15 locus. Thus, statistical significance in
the follow-up studies was declared at P#0.011 (based on a
Bonferroni correction of a=0.05 divided by 4.59, the number of
statistically independent SNPs tested in the follow-up analyses).
Since 2 cohorts measured adiponectin concentrations using an
RIA method (BLSA and InCHIANTI) whilst all others used an
ELISA method, and since one study, ALSPAC, was based on
children, rather than adults, we tested for evidence of heteroge-
neity in the combined analysis using the Q-test P-value [59].
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scheme, CEPH population. The x axis represents genomic
position in Mb (A) and in kb (B,C). All P values are derived from
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